Treatment of Plantar Warts | NCT05198180

Studies
Treatment of Plantar Warts

NCT05198180

Sponsor

Sohag University

Status

Unknown status

Last Update Posted

Jan 20, 2022Actual

Enrollment

60Estimated

Phase

Phase 3

Conditions

Plantar Wart

Interventions

Topical 30%Potassium hydroxide solution
Topical 45% hydrogen peroxide solution

Countries

Egypt

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jan 2022

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Not yet recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Feb 2022Estimated

Primary Completion Date

Jun 2022Estimated

Completion Date

Dec 2022Estimated

First Submitted Date

Dec 26, 2021

First Submission Date that Met QC Criteria

Jan 15, 2022

First Posted Date

Jan 20, 2022Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 15, 2022

Last Update Posted Date

Jan 20, 2022Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Not provided

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

This study is to compare the efficacy and safety of topical 30% potassium hydroxide solution and topical 45% hydrogen peroxide solution in treatment of plantar warts.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 3

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

60Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Potassium hydroxide group	Active Comparator	Patients with plantar warts will apply topical 30% potassium hydroxide solutions on warts	Drug: Topical 30%Potassium hydroxide solution
Hydrogen peroxide group	Active Comparator	Patients with plantar warts will use topical 45% hydrogen peroxide solution on warts	Drug: Topical 45% hydrogen peroxide solution

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Topical 30%Potassium hydroxide solution	Drug	Patients will apply the solution every day under occlusion for 3 months	Potassium hydroxide group

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change in the size of the plantar warts	Decrease in the size of warts measured by a ruler	12 weeks after end of treatment

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

confirmed diagnosis by clinical and dermoscopic examination of plantar warts

Exclusion Criteria:

history of hypersensitivity to any component used in this study
pregnancy and breastfeeding
patients who receive immune suppressive therapy
patients who received any wart treatments during the last 2 months before enrollent in the study
patients who refused participation in the study

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

12 Years

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Samar Sa Ahmed, Resident	Contact	01152471005		Summersayed156@gmail.com

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Sohag faculty of medicine		Sohag			Egypt

IPD Sharing Statement Module

Plan to Share IPD

Description

Not provided

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided